These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 44723)
1. [Identification of urinary metabolites of befunolol in dog and man principally by mass spectrometry (author's transl)]. Tohno M; Kimura K; Nagahara M; Sakai Y; Ofuji T; Nadai T Yakugaku Zasshi; 1979 Sep; 99(9):944-57. PubMed ID: 44723 [No Abstract] [Full Text] [Related]
2. [The beta-adrenergic blocking and antiarrhythmic activities of metabolites of befunolol hydrochloride (author's transl)]. Masumoto S; Inoue H; Maruyama Y Nihon Yakurigaku Zasshi; 1979 Jul; 75(5):517-25. PubMed ID: 44259 [No Abstract] [Full Text] [Related]
3. Metabolic studies on CS-359, a new beta-adrenergic blocking agent. I. Isolation and identification of the urinary metabolites of CS-359. Hayashi R; Okada M; Nakazawa T; Tanaka Y; Shimoji Y Chem Pharm Bull (Tokyo); 1975 Jun; 23(6):1173-83. PubMed ID: 241498 [No Abstract] [Full Text] [Related]
4. [The metabolism of 1-tertiary-butylamino-3-(2,3-dimethylphenoxy)-2-propanol (D-32), a new beta-blocker agent. II. Blood level, distribution, and structure of its metabolites in bile (author's transl)]. Honma S; Kanbekawa A Yakugaku Zasshi; 1975 Jun; 95(6):680-9. PubMed ID: 241825 [No Abstract] [Full Text] [Related]
5. Identification of talinolol metabolites in urine of man, dog, rat and mouse after oral administration by high-performance liquid chromatography-thermospray tandem mass spectrometry. Schupke H; Hempel R; Eckardt R; Kronbach T J Mass Spectrom; 1996 Dec; 31(12):1371-81. PubMed ID: 8990520 [TBL] [Abstract][Full Text] [Related]
6. [Studies on befunolol-metabolizing activities, especially on reducing activity (author's transl)]. Tohno M; Yamamoto T; Kajikawa N; Ofuji T Yakugaku Zasshi; 1980 Apr; 100(4):443-51. PubMed ID: 7437132 [No Abstract] [Full Text] [Related]
7. [The metabolism of the beta receptor blocker talinolol in humans--relationship between structure, polarity and amount excreted]. Oertel R; Richter K Pharmazie; 1995 Sep; 50(9):637-8. PubMed ID: 7480105 [No Abstract] [Full Text] [Related]
8. Species differences in the metabolism of pamatolol, a cardioselective beta--adrenoceptor antagonist. Hoffmann KJ; Skånberg I; Borg KO Eur J Drug Metab Pharmacokinet; 1979; 4(3):163-73. PubMed ID: 43252 [TBL] [Abstract][Full Text] [Related]
9. [Befunolol isomers and aqueous humor dynamic in man (author's transl)]. Araie M; Takase M Nippon Ganka Gakkai Zasshi; 1981 Jan; 85(1):44-9. PubMed ID: 6114631 [No Abstract] [Full Text] [Related]
10. Determination of tertatolol enantiomers in biological fluids by high-performance liquid chromatography. Lave T; Efthymiopoulos C; Koffel JC; Jung L J Chromatogr; 1991 Dec; 572(1-2):203-10. PubMed ID: 1687817 [TBL] [Abstract][Full Text] [Related]
11. Metabolism and urinary excretion of esmolol in humans. Achari R; Drissel D; Matier WL; Hulse JD J Clin Pharmacol; 1986 Jan; 26(1):44-7. PubMed ID: 2869058 [TBL] [Abstract][Full Text] [Related]
12. Rapid analysis for metabolites of 11C-labelled drugs: fate of [11C]-S-4-(tert.-butylamino-2-hydroxypropoxy)-benzimidazol-2-one in the dog. Jones HA; Rhodes CG; Law MP; Becket JM; Clark JC; Boobis AR; Taylor GW J Chromatogr; 1991 Oct; 570(2):361-70. PubMed ID: 1686775 [TBL] [Abstract][Full Text] [Related]
13. [A single dose study of topical befunolol on intraocular pressure in man (author's transl)]. Takase M; Araie M; Matsuo T Nippon Ganka Gakkai Zasshi; 1982; 86(1):87-98. PubMed ID: 6123243 [No Abstract] [Full Text] [Related]
14. Studies on metabolic reduction of befunolol in rabbit liver and kidney. Imamura Y; Nozaki Y; Imai T; Otagiri M Chem Pharm Bull (Tokyo); 1988 Feb; 36(2):708-12. PubMed ID: 2900698 [No Abstract] [Full Text] [Related]
15. Isolation and characterization of metabolites derived from 1-tert-butylamino-3-(2,3-dimethylphenoxy)-2-propanol (D-32), a new beta-blocker. Honma S; Kambekawa A Chem Pharm Bull (Tokyo); 1975 May; 23(5):1045-56. PubMed ID: 241494 [No Abstract] [Full Text] [Related]
16. [Membrane stabilizing actions of befunolol and indenolol, new beta-adrenergic receptor blocking drugs (author's transl)]. Sada H; Harada S; Kojima M; Ban T Kokyu To Junkan; 1981 Nov; 29(11):1231-7. PubMed ID: 6121358 [No Abstract] [Full Text] [Related]
17. [Ocular tissue distributions of befunolol hydrochloride, a beta-adrenergic blocking agent, after intravitreous or subconjunctival injection into the albino and pigmented rabbits]. Ishii Y; Matsumura Y; Shirasawa E; Araie M Nippon Ganka Gakkai Zasshi; 1984 Oct; 88(10):1278-86. PubMed ID: 6151807 [No Abstract] [Full Text] [Related]
18. [Effects of Kö 1366 and propranolol on hemodynamics and regional myocardial blood flow in the selective coronary hypotensive dogs (author's transl)]. Tomoike H Fukuoka Igaku Zasshi; 1975 Apr; 66(4):301-19. PubMed ID: 237808 [No Abstract] [Full Text] [Related]
19. [Toxic effect of Befunolol, a beta-adrenergic blocking agent on the in vitro retinal preparation of adult albino rabbits (author's transl)]. Honda Y; Kawano S; Negi A Nippon Ganka Gakkai Zasshi; 1981; 85(7):780-3. PubMed ID: 6118027 [No Abstract] [Full Text] [Related]
20. [Adrenergic beta-receptor blocking activity of (3-amino-2-hydroxy)propoxy-3, 4-dihydrocarbostyril derivatives in anesthetized dog (author's transl)]. Nakagawa K; Murakami N; Yoshizaki S; Tominaga M; Mori H Yakugaku Zasshi; 1974 May; 94(5):613-6. PubMed ID: 4153735 [No Abstract] [Full Text] [Related] [Next] [New Search]